Detail akcie Synairgen online

Business Summary: Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Synairgen plc revenues was not reported. Net loss decreased 31% to L3.3M. Lower net loss reflects Drug Discovery & Development segment loss decrease of 29% to L3.9M. Basic Earnings per Share excluding Extraordinary Items increased from -L0.02 to -L0.01.